Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer.
Akkermansiaceae
Microbiome
NSCLC
PD-1
PD-L1
Response to immunotherapy
Journal
AMB Express
ISSN: 2191-0855
Titre abrégé: AMB Express
Pays: Germany
ID NLM: 101561785
Informations de publication
Date de publication:
06 Jul 2022
06 Jul 2022
Historique:
received:
28
03
2022
accepted:
26
06
2022
entrez:
6
7
2022
pubmed:
7
7
2022
medline:
7
7
2022
Statut:
epublish
Résumé
The significance of Akkermansia bacteria presence in gut micobiome, mainly Akkermansia mucinifila, is currently being investigated in the context of supporting therapy and marker for response to immunotherapy in cancer patients. It is indicated that patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) respond better to treatment if this bacterium is present in the intestine.We performed next-generation sequencing of the gut microbiome from patients treated in the first or second line therapy with anti-PD-1 (anti-programmed death 1) or anti-PD-L1 (anti-programmed death ligand 1) monoclonal antibodies. In our study group of 47 NSCLC patients, the percentage of Akkermansiaceae was higher in patients with disease stabilization and with partial response to immunotherapy compared to patients with disease progression. Moreover, we found that a higher percentage of Akkermansiaceae was present in patients with squamous cell carcinoma compared to adenocarcinoma. Our study showed that Akkermansiaceae could be supporting marker for response to immunotherapies in NSCLC patients, nonetheless further in-depth studies should be conducted in the role of Akkermansiaceae in cancer immunotherapy.
Identifiants
pubmed: 35792976
doi: 10.1186/s13568-022-01428-4
pii: 10.1186/s13568-022-01428-4
pmc: PMC9259768
doi:
Types de publication
Journal Article
Langues
eng
Pagination
86Informations de copyright
© 2022. The Author(s).
Références
Int J Biol Sci. 2019 Sep 7;15(11):2381-2392
pubmed: 31595156
JAMA Oncol. 2019 Oct 01;5(10):1411-1420
pubmed: 31343665
PLoS One. 2017 Mar 1;12(3):e0173004
pubmed: 28249045
ISME J. 2012 Oct;6(10):1858-68
pubmed: 22622349
Gut Microbes. 2019;10(3):424-428
pubmed: 30339501
J Immunother Cancer. 2019 Nov 15;7(1):305
pubmed: 31730010
Mol Cell. 2019 Nov 7;76(3):359-370
pubmed: 31668929
Ann Palliat Med. 2020 Nov;9(6):4211-4227
pubmed: 33302682
Diabetes. 2014 Aug;63(8):2821-32
pubmed: 24696449
J Immunol Res. 2020 Aug 7;2020:2969287
pubmed: 32832569
mBio. 2013 Nov 05;4(6):e00692-13
pubmed: 24194538
Biomark Res. 2020 Aug 26;8:35
pubmed: 32864132
J Clin Biochem Nutr. 2018 Jul;63(1):33-35
pubmed: 30087541
PLoS One. 2013 Aug 06;8(8):e70803
pubmed: 23940645
Cancer Immunol Res. 2020 Oct;8(10):1243-1250
pubmed: 32847937
Oncoimmunology. 2018 Apr 18;7(6):e1434468
pubmed: 29872574
J Immunol Res. 2021 Feb 22;2021:6661406
pubmed: 33681388
J Immunother Cancer. 2019 Jul 23;7(1):193
pubmed: 31337439
Front Pharmacol. 2021 Sep 17;12:725583
pubmed: 34603035
Best Pract Res Clin Gastroenterol. 2017 Dec;31(6):637-642
pubmed: 29566906
Am J Cancer Res. 2019 Sep 01;9(9):2047-2063
pubmed: 31598405
Int J Antimicrob Agents. 2013 Feb;41(2):149-55
pubmed: 23294932
Sci Rep. 2019 Oct 30;9(1):15683
pubmed: 31666581
Gut Microbes. 2020 Jul 3;11(4):1030-1042
pubmed: 32240032
Diabetes. 2015 Aug;64(8):2847-58
pubmed: 25845659
Cancers (Basel). 2021 Dec 28;14(1):
pubmed: 35008287
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Front Oncol. 2020 Oct 20;10:568059
pubmed: 33194652
Int J Biol Markers. 2019 Sep;34(3):251-261
pubmed: 31436122
Ther Adv Med Oncol. 2021 Feb 15;13:1758835921992968
pubmed: 33643442